Powered by
BreastCancerTrials.org
  • ALL TRIALS

  • Register to create a profile
    Enter your treatment history for more accurate matching.

    MY PROFILE
  • MY FAVORITES

You have matched to trials (Last updated: May 22, 2022) Back to Metastatic Trial Search

and or
   Reset
Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
➤
All Trials▶ All Phases▶ Sorted by zip code: 94107▶Distance: All U.S.    Filter by Trial TypeFilter by Mutations
Close
Treatment

Brain Mets required

Brain: Leptomeningeal Mets required

BRCA1/2 (inherited)

Chemotherapy

Hormone Therapy

Radiation Oncology

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Genetics/Family History

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Support/Education

Surveys/Interviews/Registries

Close

AKT

ALK

AR

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

RB

ROS1

TP53

No travel requiredTrials coming soon to MTSAdditional metastatic cancer trials

1

NEAREST SITE: 0 miles
Mays Cancer Center, UT Health San Antonio
San Antonio, TX

VISITS: 2 visits every 3 weeks, ongoing

PHASE: NA

NCT ID: NCT03995706

Antibody Drug-Conjugate Sacituzumab Govitecan for Breast Cancer That Has Spread to the Brain

A Phase 0, Investigator Initiated Study to Determine the Bioavailability of Sacituzumab Govitecan in Breast Brain Metastasis and Glioblastoma Scientific Title

Purpose
To study if sacituzumab govitecan -- an antibody-drug conjugate -- crosses the blood-brain barrier to treat brain mets.
Who is this for?
People with metastatic (stage IV) breast cancer that has spread to the brain and who are scheduled to have surgery to remove their brain tumors.    Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy), by IV, 1 day before surgery, then 2 times every 3 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate (ADC). This means it uses an antibody that targets cancer cells to deliver a chemotherapy directly to these cells. </li> <li class="seamTextUnorderedListItem">The antibody in this drug targets <span class="highlight">TROP2</span> proteins. </li> <li class="seamTextUnorderedListItem">It delivers the chemotherapy irinotecan. Irinotecan is approved for use in many other types of cancer. </li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy) is approved for use in people with metastatic triple-negative breast cancer who have already received at least two other therapies for metastatic disease. But its use in this trial is considered experimental.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03995706' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Sacituzumab_govitecan' target='_blank'>Wikipedia: Sacituzumab Govitecan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.trodelvy.com/' target='_blank'>Immunomedics Drug Information Page: Trodelvy (Sacituzumab Govitecan-Hziy)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancertodaymag.org/pages/Fall2015/Advances-Treating-Brain-Metastases.aspx' target='_blank'>Cancer Today: Breaking the Blood-Brain Barrier</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/2019/05/01/mbc-news-11/' target='_blank'>MetastaticTrialTalk: Getting to the Target, Antibody Drug Conjugates in Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nejm.org/doi/full/10.1056/NEJMoa1814213' target='_blank'>The New England Journal of Medicine: Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer</a> </li></ul>
See more
2

NEAREST SITE: 0 miles
Virginia Oncology Associates
Norfolk, VA

VISITS: 2 visits every 3 weeks, ongoing

PHASE: II

NCT ID: NCT05113966

Trilaciclib and Sacituzumab Govitecan for Advanced Triple Negative Breast Cancer

Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting Scientific Title

Purpose
To study the safety and effects (good and bad) of giving trilaciclib (Cosela), a CDK 4/6 inhibitor, with sacituzumab govitecan-hziy (Trodelvy®).
Who is this for?
People with advanced (stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer and received at least two prior treatments.    Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trilaciclib (Cosela) by IV, 2 out of every 3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) by IV, 2 out of every 3 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trilaciclib (Cosela) is a type of targeted therapy called a CDK 4/6 inhibitor. </li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is an antibody-drug conjugate (ADC). This means it uses an antibody that targets cancer cells to deliver a chemotherapy directly to these cells.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) targets <span class="highlight">Trop2</span>, a protein that is expressed by some breast cancer cells.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05113966' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancernetwork.com/view/fda-grants-trilaciclib-plus-chemotherapy-fast-track-designation-for-locally-advanced-or-metastatic-tnbc' target='_blank'>CancerNetwork: FDA Grants Trilaciclib Plus Chemotherapy Fast Track Designation for Locally Advanced or Metastatic TNBC</a> </li></ul>
See more
3

NEAREST SITE: 0 miles
Massachusetts General Hospital Cancer Center
Boston, MA

VISITS: Weekly visits for 2 out of every 3 weeks

PHASE: I-II

NCT ID: NCT04039230

Sacituzumab Govitecan and Talazoparib for Women With Metastatic Triple Negative Breast Cancer

Phase 1b/2 Study to Evaluate Antibody-Drug Conjugate Sacituzumab Govitecan in Combination With PARP Inhibitor Talazoparib in Patients With Metastatic Breast Cancer Scientific Title

Purpose
To evaluate the safety, best dose, and effects (good and bad) of using PARP inhibitor talazoparib (Talzenna®) in combination with sacituzumab govitecan (Trodelvy).
Who is this for?
Women with metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer.    Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy), by IV, once a week, for 2 out of every 3 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The PARP inhibitor being used in this study is talazoparib (Talzenna®). It is approved for use in individuals with advanced triple-negative breast cancer and an inherited BRCA1 or BRCA2 mutation. </li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate (ADC). This means it uses an antibody that targets cancer cells to deliver a chemotherapy directly to these cells. </li> <li class="seamTextUnorderedListItem">The antibody in this drug targets <span class="highlight">TROP2</span> proteins. </li> <li class="seamTextUnorderedListItem">It delivers the chemotherapy irinotecan. Irinotecan is approved for use in many other types of cancer. </li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy) is approved to treat some metastatic triple-negative breast cancer, but its use in this trial is considered experimental.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04039230' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sacituzumab-govitecan' target='_blank'>NCI Drug Dictionary: Sacituzumab Govitecan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ascopost.com/news/april-2020/fda-approves-sacituzumab-govitecan-hziy-for-patients-with-previously-treated-metastatic-triple-negative-breast-cancer/' target='_blank'>ASCO: FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.immunomedics.com/sacituzumab-govitecan-immu-132/' target='_blank'>Immunomedics Drug Information Page: Trodelvy (Sacituzumab Govitecan)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.talzenna.com/?source=google&HBX_PK=s_talazoparib&skwid=43700039109819878' target='_blank'>Pfizer Oncology: Talzenna™</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/2019/05/01/mbc-news-11/' target='_blank'>Metastatic Trial Talk: ADCs in Breast Cancer</a> </li></ul>
See more
4

NEAREST SITE: 0 miles
Emory University/Winship Cancer Institute
Atlanta, GA

VISITS: 2 visits every 3 weeks

PHASE: II

NCT ID: NCT04448886

Sacituzumab Govitecan With or Without Pembrolizumab for Advanced HR+, HER2- Breast Cancer that is PD-L1+

Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC) Scientific Title

Purpose
To study the safety and anti-cancer activity of giving sacituzumab govitecan (Trodelvy) alone or with pembrolizumab (Keytruda®).
Who is this for?
People with locally advanced (some stage III) or metastatic (stage IV), hormone positive (ER+ and/or PR+), HER2 negative (HER2-), PD-L1 positive breast cancer who have not received more than one chemotherapy for metastatic disease.    Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®), by IV, 2 out of every 3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®), by IV, 2 out of every 3 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is an antibody-drug conjugate (ADC). This means it uses an antibody that targets cancer cells to deliver a chemotherapy drug directly to these cells.</li> <li class="seamTextUnorderedListItem">The antibody in this drug targets <span class="highlight">TROP2</span> proteins. It delivers the chemotherapy irinotecan. Irinotecan is approved for use in many other types of cancer.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is approved for use in people with metastatic triple negative breast cancer who have already received at least two other therapies for metastatic disease but its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor. It is approved to treat certain types of cancers. Its use in breast cancer is considered experimental.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PD-L1</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04448886' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-sacituzumab-govitecan-triple-negative-breast-cancer' target='_blank'>NCI Cancer Currents Blog: Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/fda-approvals-sought-for-2-pembrolizumab-indications-in-tnbc' target='_blank'>OncLive: FDA Approvals Sought for 2 Pembrolizumab Indications in TNBC</a> </li></ul>
See more
5

NEAREST SITE: 0 miles
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, CA

VISITS: 1 visit every week (2 weeks on, 1 week off), ongoing

PHASE: II

NCT ID: NCT04647916

Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases Scientific Title

Purpose
To study the anti-cancer activity, safety and side effects of giving the antibody-drug conjugate sacituzumab govitecan (Trodelvy®) to treat brain metastases (breast cancer that has spread to the brain).
Who is this for?
People with metastatic (stage IV) HER2 negative (HER2-) breast cancer that has spread to the brain.    Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®), by IV, every week (2 weeks on, 1 week off), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is an antibody-drug conjugate (ADC). This means it uses an antibody that targets cancer cells to deliver a chemotherapy directly to these cells.</li> <li class="seamTextUnorderedListItem">The antibody in this drug targets <span class="highlight">TROP2</span> proteins. It delivers the chemotherapy irinotecan. Irinotecan is approved for use in many other types of cancer.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan is approved for use in people with metastatic triple negative breast cancer who have already received at least two other therapies for metastatic disease, but its use in this trial is considered experimental.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04647916' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-sacituzumab-govitecan-triple-negative-breast-cancer' target='_blank'>NCI Cancer Currents Blog: Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.targetedonc.com/view/sacituzumab-govitecan-shows-pfs-benefit-for-patients-with-mtnbc-and-brain-metastases' target='_blank'>Targeted Oncology: Sacituzumab Govitecan Shows PFS Benefit for Patients With mTNBC and Brain Metastases</a> </li></ul>
See more
6

NEAREST SITE: 0 miles
Research Site
Duarte, CA

VISITS: Number of visits unavailable

PHASE: III

NCT ID: NCT05104866

Datopotamab Deruxtecan ADC for Metastatic HR Positive, HER2 Negative Breast Cancer

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) Scientific Title

Purpose
To study the safety, effects (good and bad), and anti-cancer activity of datopotamab deruxtecan, an experimental antibody drug conjugate (ADC).
Who is this for?
People with metastatic hormone positive (HR+) HER2 negative (HER2-) breast cancer that progressed on at least 2 lines of therapy.    Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physician's choice of chemotherapy: Capecitabine (Xeloda®), by mouth or gemcitabine (Gemzar®), eribulin (Halaven®), vinorelbine (Navelbine®), by IV</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan is an experimental antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Its antibody targets <span class="highlight">TROP2</span>, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug called DXd.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05104866' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Antibody-Drug Conjugates</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancernetwork.com/view/positive-response-activity-seen-with-datopotamab-deruxtecan-in-advanced-tnbc' target='_blank'>Cancer Network: Datopotamab Deruxtecan</a> </li></ul>
See more
7

NEAREST SITE: 0 miles
University of Chicago Medical Center
Chicago, IL

VISITS: 1 visit per week

PHASE: II

NCT ID: NCT04468061

Sacituzumab Govitecan with or without Pembrolizumab for Advanced Triple Negative or ER-Low, HER2- Breast Cancer

Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC) Scientific Title

Purpose
To study the safety and anti-cancer activity of giving the antibody-drug conjugate sacituzumab govitecan (Trodelvy) alone and in combination with the immunotherapy pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-. HER2-) or ER-Low (1%-10% ER), HER2 negative breast cancer that is PD-L1 negative, who have not yet started treatment for metastatic disease.    Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab Govitecan (Trodelvy), by IV, every week (2 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab Govitecan (Trodelvy), by IV, every week (2 weeks on, 1 week off), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate (ADC). This means it uses an antibody that targets cancer cells to deliver a chemotherapy directly to these cells. </li> <li class="seamTextUnorderedListItem">The antibody in this drug targets <span class="highlight">TROP2</span> proteins. </li> <li class="seamTextUnorderedListItem">It delivers the chemotherapy irinotecan. Irinotecan is approved for use in many other types of cancer. </li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy) is approved for use in people with metastatic triple negative breast cancer who have already received at least two other therapies for metastatic disease. But its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Pembrolizumab is a type of immunotherapy called a PD-1 inhibitor. It is approved to treat certain types of cancers but its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low. This trial is enrolling people with triple negative as well as ER-Low, HER2 negative breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04468061' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-sacituzumab-govitecan-triple-negative-breast-cancer' target='_blank'>NCI Cancer Currents Blog: Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.trodelvy.com/dosing' target='_blank'>Immunomedics Drug Information Page: Trodelvy (Sacituzumab Govitecan)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/pembrolizumab' target='_blank'>Cancer Research UK: Pembrolizumab (Keytruda)</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/' target='_blank'>NIH MedlinePlus: PDL1 (Immunotherapy) Tests</a> </li></ul>
See more
8

NEAREST SITE: 0 miles
START Midwest
Grand Rapids, MI

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT05006794

GS-9716 With Docetaxel or Sacituzumab Govitecan for Advanced Triple Negative Breast Cancer

A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies Scientific Title

Purpose
To study the best dose, safety, and side effects of the experimental targeted therapy GS-9716.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR- and HER2-) breast cancer. You must have received one line of therapy for metastatic disease.    Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GS-9716, by mouth</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®) is a chemotherapy commonly used to treat breast cancer. (Taxotere®), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GS-9716, by mouth</li> <li class="seamTextUnorderedListItem">Sacituzumab Govitecan-hziy (Trodelvy®), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GS-9716 is an experimental targeted therapy called an MCL-1 inhibitor.</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®) is a chemotherapy commonly used to treat breast cancer.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is an antibody-drug conjugate (ADC). This means it uses an antibody that targets cancer cells to deliver a chemotherapy directly to these cells.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) targets <span class="highlight">Trop2</span>, a protein that is expressed by some breast cancer cells.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05006794' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
9

NEAREST SITE: 0 miles
Massachusetts General Hospital
Boston, MA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT03401385

DS-1062a in Advanced Triple Negative Breast Cancer

Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors Scientific Title

Purpose
To study the safety, best dose, and effects (good and bad) of DS-1062a.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer who have no standard treatment options available.    Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DS-1062a</li> <li class="seamTextUnorderedListItem">2 biopsies</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DS-1062a is an investigational antibody-drug conjugate (ADC). This type of drug uses an antibody that targets cancer cells to deliver a chemotherapy directly to these cells.</li> <li class="seamTextUnorderedListItem">The antibody in this drug targets <span class="highlight">Trop2</span> proteins. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced solid tumors.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03401385' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/793720' target='_blank'>NCI Drug Dictionary: DS-1062a</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/2019/05/01/mbc-news-11/' target='_blank'>Metastatic Trial Talk: Getting to the Target, Antibody Drug Conjugates in Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>
See more

My Profile

Create a complete profile for more accurate trial matching. You can edit at any time.

BREAST CANCER DIAGNOSIS

Biomarkers Add
Placeholder
Tumor Type Add
Placeholder
Evidence of Disease Add
Placeholder
Measurable Disease Add
Placeholder
Date of MBC Diagnosis Add
Placeholder

CONFIRM DELETING ROW

Are you sure you wish to delete this?


CONFIRM DELETING USER

Are you sure?


CONFIRM PROFILE CHANGES

The changes you have made to the profile will be saved.


SAVE PROFILE CHANGES

Do you want to save all the changes made before logout?


BIOMARKERS

What is your breast cancer type based on your latest biopsy?

Select all that apply

Estrogen receptor (ER)
Progesterone receptor (PR)
HER2/neu (HER2)
BRCA1/2 (inherited)
Androgen receptor (AR)
PD-L1
PIK3CA

TUMOR TYPE

Has your tumor been described as any of the following?


EVIDENCE OF DISEASE

Where do you currently have evidence of disease?

Eyeball, socket


What is the current status of your brain mets?

The two innermost layers of tissue that cover the brain and spinal cord

Peritoneum, omentum

Esophagus, stomach, small intestine, large intestine

Ovaries, uterus, fallopian tubes

Please select the current status of your brain mets


MEASURABLE DISEASE

Are your tumors measurable?

For accurate matching, we suggest you consult with your provider.


DATE OF MBC DIAGNOSIS

What was the date of your metastatic diagnosis?

Invalid date


STAGE OF FIRST DIAGNOSIS

Have you ever received treatment for metastatic (Stage IV) breast cancer?


DEMOGRAPHICS

Biological Sex Add
Placeholder
Birth Year Add
Placeholder
Zipcode Add
Placeholder
Race Add
Placeholder
Latino/a or Hispanic Add
Placeholder

BIOLOGICAL SEX

What is your biological sex?


What is your current menopausal status?


BIRTH YEAR

What is your birth year?

Invalid birth year


ZIPCODE

What is your zipcode?

Invalid zipcode


RACE

What is your race?


Ethnicity

Do you identify as Latino/a or Hispanic?


TREATMENT HISTORY

Treatment received for metastatic breast cancer?

Note: Please be sure to enter medication, radiation, or surgery for accurate results. Otherwise, select "Skip this question" to view trials regardless of treatment received for metastatic breast cancer.


ADD METASTATIC MEDICATION
Placeholder

Is this treatment a part of a clinical trial?


Are you currently on this treatment?


Did your cancer progress on this treatment?




SHOW RADIATION TREATMENT SAVED
Placeholder

RADIATION TREATMENT (Metastatic)
Placeholder

RADIATION SITES


SHOW SURGERY SAVED
Placeholder

SURGERY
Placeholder
SURGERY / PROCEDURES (select all that apply)

ADD ALL MEDICATIONS RECEIVED FOR EARLY STAGE BREAST CANCER
SELECT BRAND NAME GENERIC NAME CATEGORY

ADD ALL MEDICATIONS RECEIVED TOGETHER
SELECT BRAND NAME GENERIC NAME CATEGORY

ADD ALL MEDICATIONS RECEIVED TOGETHER
SELECT BRAND NAME GENERIC NAME CATEGORY

Medication received for early stage breast cancer?

Note: Please be sure to enter medication(s) for accurate results. Otherwise, select "Skip this question" to view trials regardless of medication received for early stage breast cancer.


My Favorites

ADDITIONAL INFO